Overview
Congenital mesoblastic nephroma (CMN) is the most common renal neoplasm diagnosed in infants within the first month of life, often presenting as a solid renal mass 1.Diagnosis
Prenatal diagnosis possible via ultrasound, typically identifying a solid renal mass 1.
Postnatal imaging confirms heterogeneous mass characteristics, often nearly replacing the kidney 1.
Definitive diagnosis made through histopathological examination post-nephrectomy 1.Management
Radical nephrectomy is the primary treatment approach, typically performed early in life 1.
No specific adjuvant therapy is mentioned for classic CMN with negative margins and nodes 1.Special Populations
Pregnancy: Prenatal diagnosis can lead to early intervention; cesarean delivery may be necessary for maternal symptoms related to Ballantyne's syndrome 2.
Pediatrics: Early surgical intervention (radical nephrectomy) is feasible and safe in neonates 1.Key Recommendations
Perform prenatal ultrasound screening for solid renal masses to facilitate early diagnosis of CMN (Evidence: Moderate 1).
Radical nephrectomy should be considered as the first-line treatment for definitive management of CMN in neonates (Evidence: Expert opinion 1).
In cases where maternal symptoms suggestive of Ballantyne's syndrome occur alongside fetal CMN, emergent cesarean delivery may be warranted to alleviate maternal condition (Evidence: Weak 2).References
1 Holzman SA, HaDuong J, Khoury AE. Papers presented at the fall 2020 Pediatric Urologic Oncology Work Group of the Societies of Pediatric Urology meetingPrenatally Diagnosed Solid Renal Mass. Urology 2021. link
2 Takahashi H, Matsubara S, Kuwata T, Ohkuchi A, Mukoda Y, Saito K et al.. Maternal manifestation of Ballantyne's syndrome occurring concomitantly with the development of fetal congenital mesoblastic nephroma. The journal of obstetrics and gynaecology research 2014. link